Direct oral anticoagulants (DOAC) are prescribed for atrial fibrillation (AF) and venous thromboembolism (VTE) and both occur more frequently in obese patients. However, outcomes from DOAC trials included few individuals ≥120kg, and there is uncertainty whether high body weight reduces DOAC concentrations.
Purpose and methods
We investigated the relationship between factor Xa (FXa) inhibitor concentrations, body weight, and renal function, and compared them in high body weight patients with those published for unselected populations. Consecutive patients in two UK centres, weighing ≥ 120kg receiving 5mg bid apixaban or 20mg od rivaroxaban for AF or VTE were prospectively included. Peak or trough concentrations were measured using specific chromogenic assays and expressed in mean or median (5th-95th percentiles). On-therapy range was the interval from the 5th percentile trough concentration to the 95th percentile peak concentration.
One hundred patients were included; age range: 23-78, 31% were women, 58% had AF, creatinine clearance range: 67-474mL/min. Median body weight was 139kg, and 84% had BMI ≥40kg/m2. DOAC peak and trough concentrations varied from 44 to 727ng/mL and 14 to 299ng/mL, respectively. There was no linear relationship between FXa inhibitor concentrations at peak or trough and body weight or body mass index, and creatinine clearance. Apixaban troughs in AF and rivaroxaban peaks in VTE were lower than in unselected populations. However, only 2 trough concentrations were below the expected range, and 109/116 were within the on-therapy range (Figure 1).
These data indicate that obese or high body weight patients generally achieve therapeutic concentrations and hence therapeutic options should not be limited in these patients.Le texte complet de cet article est disponible en PDF.